Moderna shows bullish one-month setup on key technical signal
Aug 6, 2026, 2:42 PM EDT2 sourcesAI-analyzed
Why it may matterVerify against the original reporting
A historically reliable one-month signal suggests upside; concurrent catalyst (flu vaccine approval) adds optionality; short interest dynamics imply potential short-squeeze upside if sentiment shifts and options unwind.
AI summary
What happened, with direct paths to the underlying reporting
Moderna trades around $55 after FDA-approved flu vaccine; a historical 100-day/20-day ATR signal suggests near-term upside with an 82% one-month win rate historically. Short interest remains elevated though down 11% recently, and options positioning leans bearish, implying potential unwinding could spark a rally if sentiment shifts.
MRNA near a bullish 100-day/20-day ATR signal; 82% one-month gain historically.
Short interest: 52.40M shares, 14.3% float; ~7 days to cover.
FDA-approved flu vaccine cited as a near-term catalyst for MRNA.
Options positioning bearish; SOIR 1.055 near annual high; potential unwind.
Broker sentiment mixed: 22/24 hold or worse; 12-month target $55.12.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Moderna (MRNA) was flagged for a significant Power Inflow alert, a bullish order-flow signal. This suggests elevated buying interest from institutions and retailers. If the inflow…
Moderna's stock rose on news of a personalized cancer therapy and a stronger domestic manufacturing footprint, even as CEO Bancel cautions that China's state-supported biotech pus…
Moderna reported a breakthrough trial for a personalized cancer vaccine combining mRNA with Merck’s Keytruda, sending shares up sharply before a Thursday pullback. The data sugges…
The Treasury's expanded debt buybacks boosted risk appetite, lifting stocks. Moderna and Merck rallied on promising mRNA cancer vaccine data, supporting healthcare and broader mar…